BioSpace News Archive

CTP-543 Phase 3 Trial Initiation in Alopecia Areata Expected to Begin Fourth Quarter 2020 CTP-692 Phase 2 Trial Enrollment in Schizophrenia Expected to be Complete by Year-End 2020 Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass.--( BUSINESS WIRE )-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2020. “We continue to be committed to advancing both of o

Role will build on existing Humanigen Asia-Pacific activities and focus on regional clinical development, commercialization, business and corporate development

-- EYSUVIS™ NDA Accepted by FDA; Assigned PDUFA Goal Date of October 30, 2020 -- -- 2Q 2020 INVELTYS ® Revenue of $0.8 Million -- -- Conference Call and Webcast at 8:00 a.m. ET -- WATERTOWN, Mass.--( BUSINESS WIRE )-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the se

Orthofix Medical Inc. reported its financial results for the second quarter ended June 30, 2020. Net sales were $73.1 million, earnings per share was and adjusted EPS was.

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported first quarter fiscal 2021 revenue of $164.9 million compared to revenue of $207.7 million for the same period of fiscal 2020 despite a negative impact from the COVID-19 pandemic. The company delivered sequential revenue and patient growth each month within the quarter, wi

Second Quarter 2020 GAAP Revenue of $145 million Second Quarter 2020 GAAP Net Income of $12 million Second Quarter 2020 GAAP Diluted Earnings Per Share of $0.33 Second Quarter 2020 Adjusted Earnings Per Share of $0.48 Second Quarter 2020 Adjusted EBITDA of $31 million BEDFORD, Mass.--( BUSINESS WIRE )-- Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the second calendar quarter of 2020. PolarityTE will host a conference call and webcast today, August 6, 2020 at 8:00 a.m. ET. Highlights Total revenues were $2.27 million in Q2:20 compared to $1.33 million in Q2:19 SkinTE revenues were $0.94 million

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support efforts to broaden visibility within the US capital markets. “We are excited to have engaged Stern IR as our new investor relations firm to support us in enhancing our visibility within the US clinical and financial communities,” said

New data indicate stable kidney function across the two Fabry disease clinical studies up to 32 months New six-month Phase 2 FAB-201 data from first patient treated using AVROBIO’s plato ® gene therapy platform show continued reduction in toxic metabolite plasma lyso-Gb3 and increased leukocyte and plasma enzyme activity Sustained clinical data across multiple other measures for Phase 1 and Phase 2 trials for Fabry disease First patient h

Ortho Regenerative Technologies Inc. an emerging orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced that Ortho-R is designated as a Drug/Biologic combination product, by the FDA Office for Combination Products.